



## Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecific and trafficking of adoptively transferred T cells in mouse xenograft model

### SUPPLEMENTARY MATERIALS




**Supplementary Figure 1: CTL assay: Firefly luciferase expressing HCT116 cells and expanded human CD3<sup>+</sup> T lymphocytes were co-incubated with VT680 labeled (DOL: 2.0) or unlabeled P-cadherin LP-DART and control LP-DART at different concentrations.** After 24 hr the remaining viable cells were quantified by measuring the luciferase activity. The relative cytotoxicity profile suggested that VT680 labeling the P-cadherin LP-DART at DOL of 2.0 reduced the cytotoxic activity. No cytotoxic activity was observed in labeled or unlabeled (DOL 2.0) Control LP-DART at any concentration.




**Supplementary Figure 2: Comparison of biodistribution of P-cadherin LP-DART and P-cadherin DART (scDb).**

P-cadherin DART clears very rapidly from the system, thus limiting tumor exposure compared to P-cadherin LP-DART. (A) Cytotoxic activity of VT680 labeled and unlabeled P-cadherin DART and P-cadherin LP-DART. VT680 labeling decreased the cytotoxic activity of the bispecific antibodies. (B) *In vivo* tumor profile shows rapid clearance of P-cadherin DART compared to P-cadherin LP-DART. (C) *In vivo* FMT imaging profile demonstrates the clearance of P-cadherin DART through kidneys and minimal accumulation in kidneys. No significant kidney specific signal was observed for P-cadherin LP-DART (Figure 3A). There was no detectable signal of P-cadherin DART in any tissues other than kidneys at 96 hr upon *ex vivo* quantitation (data not shown).



**Supplementary Figure 3:** FMT images 24 hr post-adoptive transfer showing the whole-body distribution of CV815-T cells in 6–8 week old Naïve NSG mice at different concentrations ( $2 \times 10^6$ ;  $5 \times 10^6$ ;  $10 \times 10^6$  T cells). Images showed high number of T cells in liver, spleen and circulation (heart and GI signal). This pilot study helped select the cell number ( $5 \times 10^6$  T cells) for the T cell trafficking study.



**Supplementary Figure 4:** *Ex vivo* FMT quantitation shows no major difference in tumor targeting of P-cadherin LP-DART between (A) non-engrafted vs (B) PBMC engrafted HCT116 xenografts.  $n = 3-5$ /group. HCT116 cells ( $5 \times 10^6$  cells/mouse) mixed with 4 mg/mL Cultrex basement membrane extract was implanted s. c. on the dorsal right flank of 6–8-week-old NSG female mice. Seven days before randomization mice were inoculated with freshly isolated  $5 \times 10^6$  PBMC via i. p. route. Mice bearing 200–300 mm<sup>3</sup> tumors were enrolled to evaluate the effect of engraftment on P-cadherin LP-DART targeting to tumor.